EMA Authorised: Mynzepli (aflibercept) — Advanz Pharma Limited

View source ↗

Summary

The European Union has authorised Mynzepli (aflibercept) from Advanz Pharma Limited for multiple retinal diseases, including wet age-related macular degeneratio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Macular Edema
• Macular Edema
• Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• Mynzepli (aflibercept)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization. MAH: Advanz Pharma Limited. Decision date: 07/04/2026